SeekingAlpha · Aug 11, 2026
Seer, Inc. (SEER) Q2 2026 Earnings Call Transcript
Seer, Inc. (SEER) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDTCompany ParticipantsOmid Farokhzad - Founder, CEO, & Chair of the Board of...
NASDAQ · SEER
Healthcare · Biotechnology
$1.94
Down-$0.02 (-1.02%)
Updated Sep 2, 2026, 5:36 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
SEER closed at $1.94 after 21 trading sessions, down 12.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 1, 2026 | $1.96 | $1.98 | $1.93 | $1.94 | 411.46K |
| Aug 31, 2026 | $1.98 | $1.999 | $1.95 | $1.96 | 145.12K |
| Aug 28, 2026 | $2.01 | $2.0185 | $1.98 | $1.98 | 156.09K |
| Aug 27, 2026 | $2.00 | $2.04 | $2.00 | $2.01 | 102.78K |
| Aug 26, 2026 | $2.03 | $2.04 | $2.005 | $2.02 | 124.5K |
| Aug 25, 2026 | $2.05 | $2.0811 | $2.03 | $2.04 | 100.64K |
| Aug 24, 2026 | $2.05 | $2.065 | $2.02 | $2.04 | 207.12K |
| Aug 21, 2026 | $2.01 | $2.05 | $2.01 | $2.03 | 117.1K |
| Aug 20, 2026 | $2.04 | $2.07 | $2.01 | $2.02 | 176.52K |
| Aug 19, 2026 | $2.00 | $2.08 | $2.00 | $2.05 | 182.54K |
| Aug 18, 2026 | $2.02 | $2.035 | $2.01 | $2.02 | 258.29K |
| Aug 17, 2026 | $2.06 | $2.06 | $2.015 | $2.03 | 308.06K |
| Aug 14, 2026 | $2.10 | $2.13 | $2.08 | $2.08 | 126.39K |
| Aug 13, 2026 | $2.14 | $2.22 | $2.07 | $2.10 | 529.71K |
| Aug 12, 2026 | $2.02 | $2.16 | $2.02 | $2.14 | 515.09K |
| Aug 11, 2026 | $2.15 | $2.19 | $2.15 | $2.16 | 203.14K |
| Aug 10, 2026 | $2.16 | $2.19 | $2.145 | $2.16 | 150.88K |
| Aug 7, 2026 | $2.19 | $2.21 | $2.15 | $2.17 | 268.26K |
| Aug 6, 2026 | $2.18 | $2.21 | $2.16 | $2.19 | 381.38K |
| Aug 5, 2026 | $2.21 | $2.22 | $2.18 | $2.19 | 155.61K |
| Aug 4, 2026 | $2.20 | $2.23 | $2.20 | $2.21 | 288.23K |
The latest Smart Investors Daily articles mentioning SEER.
SEER research
Company profile and research snapshot.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 4, 2026 | Canaccord Genuity | Buy | — |
| Aug 13, 2024 | Morgan Stanley | Equal-Weight | — |
| Mar 5, 2024 | Morgan Stanley | Equal-Weight | — |
| Feb 21, 2023 | Morgan Stanley | Equal-Weight | — |
| Jan 4, 2023 | B of A Securities | Underperform | — |
No generated briefing is available yet.
SeekingAlpha · Aug 11, 2026
Seer, Inc. (SEER) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDTCompany ParticipantsOmid Farokhzad - Founder, CEO, & Chair of the Board of...
SeekingAlpha · Aug 11, 2026
2026-08-11. The following slide deck was published by Seer, Inc.
Benzinga · Aug 11, 2026
Seer (NASDAQ:SEER) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.27) by 14.81 percent. This is a 6.06 percent increase over losses of $(0.33) per share from the same
Benzinga · Aug 11, 2026
Seer (NASDAQ:SEER) affirms FY2026 sales outlook from $16.000 million-$18.000 million to $16.000 million-$18.000 million vs $16.250 million estimate.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning SEER.